First Mercantile Trust Co. decreased its stake in shares of Catalent Inc (NASDAQ:CTLT) by 2.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,510 shares of the company’s stock after selling 130 shares during the period. First Mercantile Trust Co.’s holdings in Catalent were worth $127,000 as of its most recent filing with the SEC.
Several other institutional investors have also added to or reduced their stakes in CTLT. Vanguard Group Inc. boosted its position in Catalent by 15.2% in the second quarter. Vanguard Group Inc. now owns 7,881,737 shares of the company’s stock valued at $181,201,000 after buying an additional 1,039,117 shares during the period. UBS Asset Management Americas Inc. raised its stake in Catalent by 23.2% in the second quarter. UBS Asset Management Americas Inc. now owns 4,252,650 shares of the company’s stock valued at $97,768,000 after buying an additional 799,498 shares in the last quarter. GW&K Investment Management LLC raised its stake in Catalent by 2.7% in the second quarter. GW&K Investment Management LLC now owns 1,755,362 shares of the company’s stock valued at $40,356,000 after buying an additional 46,305 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Catalent by 6.5% in the second quarter. Bank of New York Mellon Corp now owns 1,202,407 shares of the company’s stock valued at $27,644,000 after buying an additional 73,250 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in Catalent by 34.3% in the second quarter. Dimensional Fund Advisors LP now owns 884,597 shares of the company’s stock valued at $20,336,000 after buying an additional 226,138 shares in the last quarter.
Shares of Catalent Inc (NASDAQ:CTLT) opened at 25.98 on Friday. The firm has a 50-day moving average price of $25.34 and a 200 day moving average price of $25.68. The firm has a market capitalization of $3.24 billion and a price-to-earnings ratio of 29.19. Catalent Inc has a 12 month low of $18.92 and a 12 month high of $32.24.
Catalent (NASDAQ:CTLT) last issued its quarterly earnings data on Monday, August 29th. The company reported $0.52 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.53 by $0.01. The business earned $532.20 million during the quarter. During the same period in the prior year, the business posted $0.61 earnings per share. The company’s quarterly revenue was up 4.3% on a year-over-year basis. On average, analysts anticipate that Catalent Inc will post $1.40 EPS for the current fiscal year.
CTLT has been the topic of several research reports. Jefferies Group reissued a “hold” rating and set a $25.00 price target on shares of Catalent in a research report on Friday, June 10th. Bank of America Corp. raised Catalent from a “neutral” rating to a “buy” rating and set a $28.00 price target on the stock in a research report on Monday, June 20th. They noted that the move was a valuation call. Wells Fargo & Co. raised Catalent from a “market perform” rating to an “outperform” rating in a research report on Tuesday, June 21st. Zacks Investment Research raised Catalent from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 5th. Finally, TheStreet raised Catalent from a “sell” rating to a “hold” rating in a research report on Wednesday, August 17th. One analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $28.67.
In other Catalent news, major shareholder Blackstone Management Associat sold 17,100,705 shares of Catalent stock in a transaction on Friday, September 9th. The stock was sold at an average price of $23.58, for a total value of $403,234,623.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NASDAQ:CTLT).
Receive News & Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related companies with MarketBeat.com's FREE daily email newsletter.